OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
11 Maio 2023 - 8:00AM
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease to address the
significant unmet need in this multi-billion-dollar market, is
pleased to announce that they are now participating on the new
Webull Corporate Communication services platform. The OKYO portal
on the Webull platform will help provide the Company with a direct
line of communication with its shareholders while providing OKYO's
followers with instant notifications regarding corporate content
like company news, earnings reports, investor presentations, and
more.
“We're excited to participate on Webull’s mobile-first brokerage
platform with a unique community-driven experience,” said OKYO
Pharma’s founder and Chairman, Gabriel Cerrone. “The Webull
platform will enable OKYO Pharma to take advantage of a convenient
and efficient digital communications channel to reach the platform
of active investors while also allowing us to easily share content
with them in real-time.”
For current Webull users, be sure to follow OKYO from the Webull
app. To download the app and register for your free Webull account,
visit: https://www.webull.com/introduce.
About WebullBrokerage services offered through Webull Financial
LLC (“Webull Financial”), an SEC-registered broker-dealer and
member of the Financial Industry Regulatory Authority (FINRA) and
the Securities Investor Protection Corporation (SIPC). Investment
advisory services are offered by Webull Advisors LLC (“Webull
Advisors”), a Securities and Exchange Commission (SEC) registered
investment adviser. Webull Financial and Webull Advisors are
affiliates. All investing is subject to risk, including the
possible loss of the money you invest. Neither entity guarantees
profits or protection from losses.
About OKYOOKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a
life sciences company admitted to listing on NASDAQ and on the
standard segment of the Official List of the UK Financial Conduct
Authority and to trading on the main market for listed securities
of London Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain. For further information, please visit
www.okyopharma.com
About OK-101OK-101 is a lipid conjugated chemerin peptide
agonist of the ChemR23 G-protein coupled receptor which is
typically found on immune cells of the eye responsible for the
inflammatory response. OK-101 was developed using a
membrane-anchored-peptide (MAP) technology to produce a novel
long-acting drug candidate for treating dry eye disease. OK-101 has
been shown to produce anti-inflammatory and pain-reducing
activities in mouse models of dry eye disease and corneal
neuropathic pain; and is designed to combat washout through the
inclusion of the lipid ‘anchor’ contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular
environment.
Forward-Looking StatementsCertain statements made in this
announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the
Company's current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
For further information, please visit the Company's website at
www.okyopharma.com
The person who arranged for the release of this announcement on
behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive
Officer of OKYO.
Enquiries:
OKYO Pharma
Limited |
Gary S. Jacob,
Chief Executive Officer |
+44 (0)20 7495
2379 |
Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
|
|
|
Optiva Securities Limited |
|
|
(Broker) |
Robert Emmet |
+44 (0)20 3981 4173 |
OKYO Pharma (NASDAQ:OKYO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
OKYO Pharma (NASDAQ:OKYO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024